Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | GJB2 | P29033 | 1/20 | 0.39 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.38 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.38 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.38 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.38 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.38 |
| ▸ | GBA1 | P04062 | 1/20 | 0.36 |
| ▸ | LGALS8 | O00214 | 5/20 | 0.35 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.35 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.35 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12898607 | 1.00 | TNF (0.46) | TNFMAPK1GJB2SSTR1SSTR2 | |
| SCHEMBL12669339 | 1.00 | TNF (0.46) | TNFMAPK1GJB2SSTR1SSTR2 | |
| SCHEMBL15003149 | 1.00 | TNF (0.46) | TNFMAPK1GJB2SSTR1SSTR2 | |
| SCHEMBL9008143 | 1.00 | TNF (0.46) | TNFMAPK1GJB2SSTR1SSTR2 | |
| SCHEMBL15304386 | 1.00 | TNF (0.46) | TNFMAPK1GJB2SSTR1SSTR2 | |
| SCHEMBL14418209 | 1.00 | TNF (0.46) | TNFMAPK1GJB2SSTR1SSTR2 | |
| SCHEMBL463607 | 1.00 | TNF (0.46) | TNFMAPK1GJB2SSTR1SSTR2 | |
| SCHEMBL16254154 | 0.98 | TNF (0.47) | TNFMAPK1GJB2SSTR1SSTR2 | |
| SCHEMBL27099540 | 0.98 | TNF (0.47) | TNFMAPK1GJB2SSTR1SSTR2 | |
| SCHEMBL10648977 | 0.95 | TNF (0.51) | TNFMAPK1GJB2SSTR1SSTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9700532-B2 | iNKT cell modulators and methods of using the same | LUDWIG INSTITUTE FOR CANCER RESEARCH (CH) | 2017-07-11 | — | — | US | disclosed |
| US-20160361280-A1 | INKT CELL MODULATORS AND METHODS OF USING THE SAME | LUDWIG INSTITUTE FOR CANCER RESEARCH (CH) | 2016-12-15 | — | — | US | disclosed |
| US-9365496-B2 | iNKT cell modulators and methods of using the same | LUDWIG INSTITUTE FOR CANCER RESEARCH (CH) | 2016-06-14 | — | — | US | disclosed |
| US-20150010496-A1 | INKT CELL MODULATORS AND METHODS OF USING THE SAME | THE UNIVERSITY OF BIRMINGHAM (GB) | 2015-01-08 | — | — | US | disclosed |
| WO-2013079687-A1 | INKT CELL MODULATORS AND METHODS OF USING THE SAME | THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD (GB) | 2013-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160361280-A1 | INKT CELL MODULATORS AND METHODS OF USING THE SAME | PBK, NFATC1, UGCG | TNF 1072/4885MAPK1 4336/4885GJB2 4101/4885 |
| US-20150010496-A1 | INKT CELL MODULATORS AND METHODS OF USING THE SAME | PBK, NFATC1, UGCG | TNF 1072/4885MAPK1 4336/4885GJB2 4101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.